Notice of special administration instructions for Zemaira. Read more here X


The first and only of its kind to use next-generation sequencing.

DNA1 puts your patient at the center of diagnosis

Click each section for more information.

Targeted genotyping

  • Tests for multiple allele combinations to help you identify the risk of Alpha-1.
  • DNA1 looks beyond S and Z at the most common, clinically relevant alleles.

Next-generation sequencing

  • There are over 120 known variants to the SERPINA1 gene.10
  • Provides full genetic sequencing of the SERPINA1 gene to identify known and previously undiscovered variants.

Clinical chemistry

  • Is the only test available that screens for both A1AT protein levels and C-reactive protein (CRP) levels to give context to the A1AT results and help prevent false negatives.*

CRP, like A1AT, is an acute-phase protein, which means they are both elevated with inflammation. This CRP test is not a high-sensitivity test; it is used as a measurement of inflammation.

Isoelectric focusing (IEF)

  • IEF phenotyping results serve as a confirmatory step for genotyping results, giving added confidence that results are accurate.

Watch an Alpha-1 expert discuss the importance of testing and early diagnosis.

Important Safety Information

Alpha1-Proteinase Inhibitor (Human), Zemaira® is indicated for chronic augmentation and maintenance therapy for adults with alpha1-proteinase inhibitor (A1-PI) deficiency and emphysema. No clinical data are available demonstrating the effect of augmentation therapy with Zemaira or any A1-PI product on the progression of emphysema in A1-PI deficiency.

Zemaira is not indicated for lung disease patients in whom severe A1-PI deficiency has not been established.

Zemaira is contraindicated in patients with a history of severe systemic reactions to the product or to A1-PI protein, including anaphylaxis. Due to the risk of severe hypersensitivity, Zemaira is also contraindicated in immunoglobulin A-deficient patients with antibodies against IgA.

Use caution in administering Zemaira to patients who have experienced anaphylaxis or severe systemic reactions to another A1-PI product. Patients with selective or severe IgA deficiency can develop antibodies to IgA and are at greater risk of such reactions. If anaphylactic or severe anaphylactoid reactions occur during infusion, discontinue immediately.

In pre-licensure clinical studies, the following adverse reactions were reported in at least 5% of subjects receiving Zemaira: headache, sinusitis, upper respiratory infection, bronchitis, asthenia, increased cough, fever, injection-site hemorrhage, rhinitis, sore throat, and vasodilation.

Zemaira is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Please see full prescribing information for Zemaira.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.

Zemaira is manufactured and distributed by CSL Behring LLC.
Zemaira® is a registered trademark of CSL Behring LLC.
DNA1 Advanced Alpha-1 Screening™ is a trademark of CSL Behring LLC.

© 2018 CSL Behring LLC. The product information presented on this site is intended for US residents only. ZMR03-13-0022(3) 6/2015